Induction of anti-Plasmodium immunity following subpatent infection with live erythrocytic stages and drug cure
An effective malaria vaccine remains an important priority for the millions of people living in malaria endemic regions. Subambitious goals for the development of a vaccine have been set, which aim to achieve a licensed first-generation P. falciparum malaria vaccine with more than 50% protective efficacy against severe disease and death, lasting for at least 1 year by 2015. These goals were set in the context of a subunit vaccine. However, a whole-parasite vaccine might be expected to induce substantially superior protection. Our group has been focusing on low dose blood-stage parasites as a valid vaccine approach, and we present here the relevant methodology for this.
Methods in Molecular Biology
Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)